Oblimersen sodium (G3139) targeting bcl-2 mRNA overcomes acquired resistance to rituximab and sensitizes rituximab-resistant non-Hodgkin's lymphoma (NHL) cells to rituximab-associated complement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results